BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 29904979)

  • 1. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
    Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
    Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of sodium butyrate and cisplatin on expression of EMT markers.
    Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
    PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells.
    Yang M; Ma B; Shao H; Clark AM; Wells A
    BMC Cancer; 2016 Jul; 16():419. PubMed ID: 27387344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments.
    Raghavan S; Mehta P; Xie Y; Lei YL; Mehta G
    J Immunother Cancer; 2019 Jul; 7(1):190. PubMed ID: 31324218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.
    Kielbik M; Szulc-Kielbik I; Klink M
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FPR2 participates in epithelial ovarian cancer (EOC) progression through RhoA-mediated M2 macrophage polarization.
    Xie X; He J; Wang Q; Liu Y; Chen W; Shi K
    J Ovarian Res; 2021 Dec; 14(1):177. PubMed ID: 34930387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Brum MCM; Dos Santos Guimaraes I; Ferreira LB; Rangel LBA; Maia RC; Nestal De Moraes G; Gimba ERP
    Oncol Rep; 2021 Feb; 45(2):652-664. PubMed ID: 33416171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8/STAT3 signaling.
    Ning Y; Cui Y; Li X; Cao X; Chen A; Xu C; Cao J; Luo X
    Biomed Pharmacother; 2018 Jul; 103():262-271. PubMed ID: 29656182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway.
    Liu CY; Xu JY; Shi XY; Huang W; Ruan TY; Xie P; Ding JL
    Lab Invest; 2013 Jul; 93(7):844-54. PubMed ID: 23752129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression.
    Comito G; Giannoni E; Segura CP; Barcellos-de-Souza P; Raspollini MR; Baroni G; Lanciotti M; Serni S; Chiarugi P
    Oncogene; 2014 May; 33(19):2423-31. PubMed ID: 23728338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.
    Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X
    Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced invasion of lung adenocarcinoma cells after co-culture with THP-1-derived macrophages via the induction of EMT by IL-6.
    Dehai C; Bo P; Qiang T; Lihua S; Fang L; Shi J; Jingyan C; Yan Y; Guangbin W; Zhenjun Y
    Immunol Lett; 2014 Jul; 160(1):1-10. PubMed ID: 24698728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.